• André Vicente Esteves de CarvalhoEmail author


Psoriasis is an inflammatory skin disease whereby erythematous scaling plaques appear on otherwise healthy skin. Genetic and environmental factors gather to induce the outbreak of lesions. Physiopathology of the disease is an immune imbalance driven mainly by cellular immunity (CD4+ T lymphocytes) and release of different cytokines (TNF-α, IL-17, IL-23, among others). The disease has different clinical presentations according to the extent of the disease, location, or presence of pustules. Arthritis may also be a feature in up to one-third of patients and other comorbidities also may be present (for example, metabolic syndrome and inflammatory bowel disease). Treatment depends on the extension and severity of the disease and may range from topical treatment to systemic immunosuppressants.


Psoriasis Erythematous scaling Inflammatory disease Photochemotherapy Immunosuppressants Biologics 



Auspitz’s sign

Pinpoint bleeding following methodic curettage of the scales in a psoriatic lesion.


Histopathologic term referring to elongated and widened rete ridges, which look like a club.


Scaling erythematous dermatitis that affects 90% or more of the body surface area. Psoriasis is one of the causes of erythroderma, but other diseases may also be causes.

Sézary syndrome

A late stage of cutaneous T-cell lymphoma that is characterized by the epidermotropism of neoplastic CD4+ T lymphocytes, which form microabscesses (Pautrier’s microabscesses). Lymphadenopathy and presence of atypical T cells (Sézary cells) in the peripheral blood are signs of late-stage disease.

Tricophytoid lesion

Lesion similar to a skin fungal infection (tinea). Its characteristic is a annular lesion with a more prominent border (active border), where the fungal activity resides.

von Zumbusch psoriasis

Also called Von Zumbusch generalized pustular psoriasis, this is a severe and generalized form of pustular psoriasis. Pus consists of neutrophils. Drugs, emotional stress, infections, and sudden withdrawal of systemic steroids are some of the eliciting factors.


  1. 1.
    Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.CrossRefPubMedGoogle Scholar
  2. 2.
    Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–20.Google Scholar
  3. 3.
    Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol. 1981;61(4):344–6.PubMedGoogle Scholar
  4. 4.
    Swanbeck G, Inerot A, Martinsson T, Wahlström J, Enerbäck C, Enlund F, et al. Age at onset and different types of psoriasis. Br J Dermatol. 1995;133(5):768–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Miot HA, Miot LDB, Lopes PS, Haddad GR, Marques SA. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J Eur Acad Dermatol Venereol. Blackwell Publishing Ltd. 2009;23(10):1173–7.Google Scholar
  6. 6.
    Patrizi A, Venturi M, Scorzoni R, Pazzaglia M, Malavolta N, Bardazzi F. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol. 2014;149(2):177–84.PubMedGoogle Scholar
  7. 7.
    van de Kerkhof PC, Nestle FO. Psoriasis. In: Bolognia JL, Jorizzo J, Schaffer JV, editors. Dermatology. 3rd ed. London: Saunders; 2012. p. 135–56.Google Scholar
  8. 8.
    Goh B-K, Chan RKW, Sen P, Theng CTS, Tan H-H, Wu Y-J, et al. Spectrum of skin disorders in human immunodeficiency virus-infected patients in Singapore and the relationship to CD4 lymphocyte counts. Int J Dermatol. Blackwell Publishing Ltd. 2007;46(7):695–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Egeberg A. Psoriasis and comorbidities. Epidemiological studies. Dan Med J. 2016;63(2):1–11.Google Scholar
  10. 10.
    Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA Am Med Assoc. 2006;296(14):1735–41.CrossRefGoogle Scholar
  11. 11.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.CrossRefPubMedGoogle Scholar
  12. 12.
    Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;5(9):699–711.CrossRefPubMedGoogle Scholar
  13. 13.
    Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt. 1982;33(4):214–7.PubMedGoogle Scholar
  14. 14.
    Boehncke W, Schön MP. Seminar psoriasis. Lancet. Elsevier Ltd. 2015;386(9997):983–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Nickoloff BJ, Qin J-Z, Nestle FO. Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol. 2007;33(1–2):45–56.CrossRefPubMedGoogle Scholar
  16. 16.
    Nestle FO. Plasmacytoid predendritic cells initiate psoriasis through interferon- production. J Exp Med. 2005;202(1):135–43.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci. Blackwell Publishing Inc. 2010;1183(1):211–21.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015 Mar;27(2):127–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. BMJ Publishing Group Ltd and European League Against Rheumatism. 2005;64(Suppl 2):ii18–23. discussion ii24–5.Google Scholar
  20. 20.
    Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Adişen E, Gürer MA. Therapeutic options for palmoplantar pustulosis. Clin Exp Dermatol.; Blackwell Publishing Ltd. 2010;35(3):219–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Edwards F, de Berker D. Nail psoriasis: clinical presentation and best practice recommendations. Drugs.; Springer International Publishing. 2009;69(17):2351–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol. 2005;15(4):279–83.PubMedGoogle Scholar
  24. 24.
    Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. Wiley Subscription Services, Inc., A Wiley Company. 2009;61(2):233–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Nast A, Boehncke W-H, Mrowietz U, Ockenfels H-M, Philipp S, Reich K, et al. S3 – guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatologischen Ges = J German Soc Dermatol: JDDG. Blackwell Publishing Ltd. 2012;10:S1–95.Google Scholar
  26. 26.
    Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010;28(3):304–10.PubMedGoogle Scholar
  27. 27.
    Elder DE. Lever’s histopathology of the skin. Philadelphia: Wolters Kluwer Health; 2014.Google Scholar
  28. 28.
    Nast A, Rosumeck S, Erdmann R, Dressler C, Werner RN. Current guidelines in dermatology: a selection of clinically relevant recommendations. Hautarzt. 2016;67:391.CrossRefPubMedGoogle Scholar
  29. 29.
    Morison W, Richard E. PUVA photochemotherapy and other phototherapy modalities. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Edinburgh: Elsevier Health Sciences; 2013. p. 279–90.Google Scholar
  30. 30.
    Callen JP, Kulp-Shorten C. Methotrexate. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Edinburgh: Elsevier Health Sciences; 2013. p. 169–81.Google Scholar
  31. 31.
    Patton T, Ferris LK. Systemic retinoids. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Edinburgh: Elsevier Health Sciences; 2013. p. 252–68.Google Scholar
  32. 32.
    Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555–6.PubMedGoogle Scholar
  33. 33.
    Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991;324(5):277–84.CrossRefPubMedGoogle Scholar
  34. 34.
    Mehlis S, Gordon K. Tumor necrosis factor (TNF) inhibitors. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Edinburgh: Elsevier Health Sciences; 2013. p. 307–18.Google Scholar
  35. 35.
    Amgen. Enbrel full prescribing information [Internet]. 2016 [cited 2016 Apr 10]. Available from:
  36. 36.
    Janssen. Remicade full prescribing information [Internet]. 2016 [cited 2016 Apr 10]. Available from:
  37. 37.
    Abbvie. Humira full prescribing information [Internet]. 2016 [cited 2016 Apr 10]. Available from:
  38. 38.
    Janssen. Stelara full prescribing information [Internet]. [cited 2016]. Available from:
  39. 39.
    Celgene. Otezla full prescribing information [Internet]. 2016 [cited 2016 Apr 10]. Available from:
  40. 40.
    Novartis. Cosentyx full prescribing information [Internet]. [cited 2016]. Available from:

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  1. 1.Irmandade Santa Casa de Misericórdia de Porto AlegrePorto AlegreBrazil

Personalised recommendations